Four psychedelic-news items from this week look a lot clearer when you go back to the underlying documents instead of relying on summary coverage.
Senate Bill Would Create a VA Novel Therapeutics Office
Congress.gov shows that S.4220, the Veterans Health Administration Novel Therapeutics Preparedness Act, was introduced in the Senate on March 26, 2026. Sen. Tim Sheehy's official release the next day adds the operational detail that matters most: the bill would establish a dedicated Office of Novel Therapeutics within the VA and prepare the department to evaluate and implement emerging therapies through centralized governance, workforce readiness planning, and clinical implementation infrastructure within the Veterans Health Administration.
That makes this a more concrete institutional story than a generic "Washington is interested in psychedelics" headline. The real move is administrative preparation inside the VA before newer therapies fully arrive in routine care.
The Microdosing Paper Supports a Day-Of Effect More Than a Lasting One
The direct paper behind this item is PMID 41073618, titled Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days. According to the abstract, the study drew on a naturalistic, prospective, international survey of adults who microdose (N = 1,435) and compared within-person changes across six domains of psychological functioning.
The results were specific. The authors found higher ratings of wellbeing, productivity, creativity, connectedness, contemplation, and focus on microdosing days than on non-microdosing days. For creativity, the increase was more pronounced among respondents with a history of larger-dose psychedelic use. But the paper is also cautious in a way many headlines are not. The authors explicitly describe the study as observational and exploratory and say the findings should be interpreted carefully.
So the strongest direct-source read is not that microdosing has now been proven as a broad mental-health intervention. It is that a large diary-based study found a consistent same-day self-report bump on dosing days.
FDA Lifts the GH001 Hold, and GH Research Is Framing the Next Step as Phase 3
GH Research's own January 5, 2026 release says FDA lifted the clinical hold on the company's IND for GH001, clearing the way for U.S. subject enrollment and supporting a planned global Phase 3 initiation in 2026.
The company also framed the efficacy case using highlights from its previously reported GH001-TRD-201 phase 2b trial. Those figures are more precise than the usual upbeat summary language: -15.5 placebo-adjusted MADRS reduction on Day 8, 57.5% remission on Day 8, and 73% remission at 6 months with infrequent dosing, around four treatments on average. GH Research also says the median psychoactive experience was about 11 minutes and that 99% of patients were discharge-ready within one hour of dosing.
That is the clearest direct-source reason this item matters. The hold lift is not just a procedural green light. GH is presenting it as the bridge from a strong phase 2b package into a pivotal program.
Ibogaine's Mechanism Is Not Just "Weird," It Is Multi-Transporter by Design
The ibogaine source is also sharper when named directly. The cited preprint is Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Interactions Underlie Polypharmacological Action. The authors argue that ibogaine and noribogaine do not fit neatly into a single-target model. Instead, they report effects across multiple monoamine-transporter systems at once.
In the preprint, ibogaine compounds inhibit VMAT2 and plasma-membrane monoamine transporters including SERT, and the authors also identify OCT2 as another target. They say noribogaine showed dual inhibition of VMAT2 and SERT with comparable potency, which helps explain why ibogaine's neurochemical profile has resisted simpler categories. Their label for that framework is matrix pharmacology.
That is a better summary than treating the story as just one more colorful ibogaine mystery. The paper's actual claim is that ibogaine may work through a genuinely unusual multi-transporter mechanism.
Lykos Still Looks Like the Least Source-Clean Item in the Digest
The one item here that still resists a cleaner direct-source treatment is the Lykos reshuffling story. According to Double Blind, the company remains in a period of internal and ownership change after the FDA rejection, with outside investors playing a larger role and Rick Doblin returning to a more visible position around the project.
That is why this item stays lighter than the others. Unlike the VA bill, the microdosing paper, the GH001 hold lift, and the ibogaine preprint, this is still best treated as reported coverage rather than a direct-source corporate update.